Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.

    J Eur Acad Dermatol Venereol 2017 Sep 9;31(9):1401-1424. Epub 2017 Aug 9.
    Department of Dermatology and Venereology, University Hospital of Cologne, Cologne, Germany.
    The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this guideline provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes of systemic sclerosis with diseases of the rheumatological spectrum.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
    Source Status
    http://dx.doi.org/10.1111/jdv.14458DOI ListingPossible

    Similar Publications

    European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis.
    J Eur Acad Dermatol Venereol 2017 Oct 8;31(10):1581-1594. Epub 2017 Aug 8.
    Department of Dermatology and Venereology, University Hospital of Cologne, Cologne, Germany.
    The term 'sclerosing diseases of the skin' comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. Read More
    Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance.
    Curr Opin Rheumatol 2004 Nov;16(6):723-32
    Division of Rheumatology, The University of Texas-Houston Health Science Center at Houston, 6431 Fannin, Houston, TX 77030, USA.
    Purpose Of Review: Systemic sclerosis, or scleroderma, is associated with a variety of autoantibodies, each of them having their own clinical associations. The fibrosing disorders, other than systemic sclerosis, represent a diverse group of diseases with systemic or localized effect and with limited understanding of their pathogenesis. The purpose of this review is to analyze the literature on the clinical usefulness of examining serum autoantibodies in patients with known or suspected scleroderma and fibrosing disorders. Read More
    Sclerosing disorders of the skin: an overview with focus on histopathological features.
    Am J Dermatopathol 2014 Oct;36(10):763-80
    *Associate Professor of Dermatology, Department of Dermatology, American University of Beirut-Medical Center, Beirut, Lebanon; and †Professor of Dermatology and Pathology, Head, Dermatopathology Section, Vice Chairman, Department of Dermatology, Boston University School of Medicine, Boston, MA.
    Sclerosing disorders of the skin consist of a heterogeneous spectrum of entities that share in common cutaneous sclerosis with excessive local accumulation of collagen and/or other extracellular matrix components in the dermis, subcutaneous tissue, and/or underlying soft tissues. The clinical course of these diseases varies from benign disease with a localized skin involvement to systemic, life-threatening disorders. Thus, a correct diagnosis is extremely significant as these disorders are very different in terms of pathogenesis, course, treatment, and outcome. Read More
    Cutaneous and subcutaneous inflammatory sclerosis syndromes.
    Arch Dermatol 1982 Nov;118(11):886-90
    Systemic scleroderma and localized scleroderma (morphea) show comparable changes on skin biopsy specimens, and a distinction has often been made on the basis of Raynaud's phenomenon, organ involvement, and laboratory abnormalities characteristically seen in systemic scleroderma. Critical evaluation not only of patients with localized scleroderma but also of those with eosinophilic fasciitis, morphea profunda, and acral pansclerotic morphea has disclosed Raynaud's phenomenon, organ involvement, and laboratory abnormalities typical of systemic scleroderma in a small percentage of patients. Histologically, all five conditions show similar inflammation and sclerosis of the skin, the primary difference being the depth at which these changes occur. Read More